Compare Edwards Lifesciences Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 47,653 Million (Large Cap)
29.00
NA
0.00%
-2,400.00
0.00%
0.00
Revenue and Profits:
Net Sales:
1,570 Million
(Quarterly Results - Dec 2025)
Net Profit:
64 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.53%
0%
-1.53%
6 Months
5.47%
0%
5.47%
1 Year
20.4%
0%
20.4%
2 Years
-11.97%
0%
-11.97%
3 Years
6.77%
0%
6.77%
4 Years
-20.92%
0%
-20.92%
5 Years
-0.32%
0%
-0.32%
Edwards Lifesciences Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.70%
EBIT Growth (5y)
4.60%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
1.58
Tax Ratio
10.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.75%
ROCE (avg)
29.61%
ROE (avg)
22.80%
Valuation key factors
Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
4.31
EV to EBIT
27.19
EV to EBITDA
24.76
EV to Capital Employed
5.92
EV to Sales
7.40
PEG Ratio
6.47
Dividend Yield
NA
ROCE (Latest)
21.76%
ROE (Latest)
14.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 172 Schemes (38.44%)
Foreign Institutions
Held by 509 Foreign Institutions (32.29%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,569.60
1,553.10
1.06%
Operating Profit (PBDIT) excl Other Income
420.20
472.30
-11.03%
Interest
0.00
0.00
Exceptional Items
-308.90
-117.20
-163.57%
Consolidate Net Profit
64.20
292.30
-78.04%
Operating Profit Margin (Excl OI)
240.50%
278.90%
-3.84%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 1.06% vs 1.36% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -78.04% vs -12.98% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,067.60
5,439.50
11.55%
Operating Profit (PBDIT) excl Other Income
1,786.90
1,599.50
11.72%
Interest
20.40
19.80
3.03%
Exceptional Items
-512.50
-41.60
-1,131.97%
Consolidate Net Profit
1,056.00
1,396.00
-24.36%
Operating Profit Margin (Excl OI)
268.70%
265.50%
0.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 11.55% vs 8.57% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -24.36% vs 14.43% in Dec 2024
About Edwards Lifesciences Corp. 
Edwards Lifesciences Corp.
Pharmaceuticals & Biotechnology
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Company Coordinates 
Company Details
1 Edwards Way , IRVINE CA : 92614-5688
Registrar Details






